Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Peer-Reviewed Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Batf2em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Batf2em1/Cya

Common Name
Batf2-KO
Product ID
S-KO-20232
Backgroud
C57BL/6JCya
Strain ID
KOCMP-74481-Batf2-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Batf2-KO Mouse (Catalog S-KO-20232) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Batf2-KO
Strain ID
KOCMP-74481-Batf2-B6J-VB
Gene Name
Batf2
Product ID
S-KO-20232
Gene Alias
B-ATF-2
Background
C57BL/6JCya
NCBI ID
74481 (Mouse)
Modification
Conventional knockout
Chromosome
Chr 19 (Mouse)
Phenotype
MGI:1921731
Datasheet
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000045042
NCBI Transcript ID
NM_028967
Target Region
Exon 3
Size of Effective Region
~2.6 kb
Overview of Gene Research
BATF2, also known as basic leucine zipper ATF-like transcription factor 2, is a transcription factor emerging as an important regulator in both the innate immune system and cancer-related processes. It is involved in various signaling pathways such as PTEN/AKT/β-catenin, PI3K-AKT, and is associated with interferon-activated immune response [1,3,4,6]. In the immune system, it impacts pro-inflammatory cytokine responses, and in cancer, it can act as a tumor suppressor [1,3,5,6,7]. Genetic models, especially KO mouse models, have been crucial in studying its functions.

In gastric cancer, BATF2 overexpression increased 5-Fu sensitivity, inhibited the ABCG2 drug transporter, and reduced the stem-like properties of cancer cells through the PTEN/AKT/β-catenin pathway, highlighting its role in regulating chemoresistance [1]. In glioblastoma multiforme, BATF2 inhibited glioma growth and myeloid-derived suppressor cells (MDSCs) recruitment. BATF2-overexpressing glioma cell-derived extracellular vesicles inhibited MDSCs chemotaxis, and the abundance of BATF2-positive extracellular vesicles in plasma could distinguish different stages of glioma [2]. In non-small cell lung cancer, BATF2 knockout mice studies showed that BATF2 inhibits programmed death-ligand 1 expression via the PI3K-AKT pathway and enhances CD8+ T-cell infiltration, suggesting its potential as a biomarker for immunotherapy efficacy [6].

In summary, BATF2 plays essential roles in the immune response and cancer development. Model-based research, particularly KO mouse models, has revealed its significance in diseases like gastric cancer, glioblastoma, and non-small cell lung cancer. It is involved in regulating chemoresistance, tumor growth, immune cell recruitment, and immune checkpoint molecule expression, providing insights for potential therapeutic strategies.

References:
1. Cao, Longlong, Weng, Kai, Li, Lujie, Xie, Jianwei, Li, Ping. 2024. BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/β-catenin pathway. In Theranostics, 14, 7007-7022. doi:10.7150/thno.98389. https://pubmed.ncbi.nlm.nih.gov/39629124/
2. Zhang, Xin, Liu, Yi, Dai, Lei, Zheng, Lei, Deng, Hongxin. 2021. BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells. In Oncogene, 40, 1516-1530. doi:10.1038/s41388-020-01627-y. https://pubmed.ncbi.nlm.nih.gov/33452462/
3. van der Geest, Rick, Peñaloza, Hernán F, Xiong, Zeyu, Bain, William G, Lee, Janet S. 2023. BATF2 enhances proinflammatory cytokine responses in macrophages and improves early host defense against pulmonary Klebsiella pneumoniae infection. In American journal of physiology. Lung cellular and molecular physiology, 325, L604-L616. doi:10.1152/ajplung.00441.2022. https://pubmed.ncbi.nlm.nih.gov/37724373/
4. Le, Duy T, Florez, Marcus A, Kus, Pawel, Malovannaya, Anna, King, Katherine Y. 2023. BATF2 promotes HSC myeloid differentiation by amplifying IFN response mediators during chronic infection. In iScience, 26, 106059. doi:10.1016/j.isci.2023.106059. https://pubmed.ncbi.nlm.nih.gov/36824275/
5. Zhou, Jie, Lei, Zengjie, Chen, Jianfang, Li, Jianjun, Liang, Houjie. . Nuclear export of BATF2 enhances colorectal cancer proliferation through binding to CRM1. In Clinical and translational medicine, 13, e1260. doi:10.1002/ctm2.1260. https://pubmed.ncbi.nlm.nih.gov/37151195/
6. Liu, Junwei, Li, Jie, Tuo, Zhan, Hu, Weidong, Liu, Jun. 2023. BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer. In The Journal of biological chemistry, 299, 105302. doi:10.1016/j.jbc.2023.105302. https://pubmed.ncbi.nlm.nih.gov/37777155/
7. Wen, Haojie, Tang, Jinyong, Cui, Yi, Hou, Minhua, Zhou, Juan. 2022. m6A modification-mediated BATF2 suppresses metastasis and angiogenesis of tongue squamous cell carcinoma through inhibiting VEGFA. In Cell cycle (Georgetown, Tex.), 22, 100-116. doi:10.1080/15384101.2022.2109897. https://pubmed.ncbi.nlm.nih.gov/35949109/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research